Clinical trials for preventative HIV gel

By Bizclik Editor

 

Scientists in South Africa are holding clinical trials to test a gel they believe could reduce the risk of women being infected with HIV.

The gel is being tested at seven centres and according to Professor Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute, is the first South African team of scientists to head a multi-site trial.

Previously, multi-site trials were led by international scientists working with local peers.

 

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of African Business Review, click here.

 

"The planning for the Facts study is well under way and we hope to be in the field by August," said Rees.

The Tenofovir vaginal gel is seen as a positive breakthrough for HIV prevention. It proved 39 percent effective at protecting young women from HIV and halved the risk of Herpes HSV-2, according to the Caprisa 004 study in KwaZulu-Natal.

The Facts study aims to confirm these results.

Share

Featured Articles

Abu Dhabi Airports prepares for Terminal A opening

A decade in the making, Abu Dhabi International Airport welcomes 6,000 volunteers to test operational readiness of stunning new Terminal A building

Business Chief expands portfolio with new look and coverage

Business Chief Middle East & Africa launches with fresh new look and extended coverage of the region, with exclusive executive interviews and insights

How Octopus Energy grew to become an industry giant

Octopus Energy continues to grow after a deal was agreed to acquire Shell Energy in the UK and Germany, taking its customer base to almost seven million

Perkbox CEO: How to support employees through tough times

Human Capital

How Middle East is embracing the future of digital finance

Corporate Finance

UAE Lulu Group shifts business for global growth and IPO

Corporate Finance